Abstract: A thin-film transistor and a manufacturing method thereof are characterized in that: the active layer is a group IV-VI compound semiconductor film; the group IV-VI compound is one of geranium sulfide (GeS), germanium selenide (GeSe), germanium telluride (GeTe), tin selenide (SnSe), and tin telluride (SnTe) or a ternary, quaternary, or quinary compound thereof; the active layer is deposited by sputtering; and thermal annealing is performed after the active layer is deposited. The thin-film transistor has high carrier mobility and a high current on/off ratio and therefore meets the needs of high-resolution display development.

Abstract: A light sensing circuit for solving the problem of low reliability in illumination detection includes a photo transistor having a gate, a drain and a source; a first transistor electrically connecting between the gate and source of the photo transistor; a first capacitor electrically connecting between the gate and the drain of the photo transistor; a second transistor electrically connecting with the drain of the photo transistor, the first capacitor, and a data signal; a second capacitor electrically connecting between the source of the photo transistor and a ground contact; a third transistor electrically connecting with the photo transistor, the first transistor, and the second capacitor; and a switch adapted to alternatively connect the third transistor with a buffer or a zero signal. A control method of the above light sensing circuit is also disclosed. Therefore, the above identified problem can be surely solved.

Abstract: A method for producing a thin film transistor includes forming a transistor prototype on a substrate. The transistor prototype includes two transparent electrodes adapted to form a source and a drain of a thin film transistor. Next, the two transparent electrodes of the transistor prototype are exposed in an environment full of a plasma. The plasma conducts a surface treatment on the two transparent electrodes of the transistor prototype to form the thin film transistor. The method can solve the problem of excessive contact resistance of the transparent conductive films of conventional thin film transistors.

Abstract: A method for producing a thin film transistor includes forming a transistor prototype on a substrate. The transistor prototype includes two transparent electrodes adapted to form a source and a drain of a thin film transistor. Next, the two transparent electrodes of the transistor prototype are exposed in an environment full of a plasma. The plasma conducts a surface treatment on the two transparent electrodes of the transistor prototype to form the thin film transistor. The method can solve the problem of excessive contact resistance of the transparent conductive films of conventional thin film transistors.

Abstract: The present application provides compositions and methods useful for detecting and monitoring acquired aplastic anemia.

Abstract: A method for producing a thin film transistor includes forming a transistor prototype on a substrate, with the transistor prototype including a face having a to-be-treated portion. The to-be-treated portion of the transistor prototype is exposed in an environment full of a supercritical fluid. The supercritical fluid conducts a surface treatment on the to-be-treated portion of the transistor prototype to form a thin film transistor. The method can solve the problem of too many defects of the thin film transistor resulting from a low-temperature process.

Abstract: The present application provides compositions and methods useful for treating and diagnosing diseases and disorders associated with moesin activation.

Abstract: A halogenated dideoxy sugar derivative, having the following general structure I wherein X is halogen, R1 and R2 are H or Br; R3 and R4 are OH or OAc. The compounds 1-14 of the current invention has strong inhibition effect on human nasopharyngeal cancer CNE-2Z cells, human lung cancer A549 cells. human colon cancer HT-29 cells, human liver cancer Bel-7402 cells, human rectum cancer cells HCE 8693, human stomach cancer BGC-803 cells, human esophagus cancer CaEs-17 cells, human breast cancer cells MCF-7, human ovarian cancer cells A2780, pancreatic cancer cells PC-3, human bladder cells EJ, human brain glia cells TG-905, human leukemia cells K562, human melanoma M 14 cells and human anaplastic thyroid carcinoma TA-K cells. They can be used to prepare anti-tumor medicament and have significant clinic value.

Abstract: The present application provides compositions and methods useful for treating and diagnosing diseases and disorders associated with moesin activation.

Abstract: Developed here is a mitotic network comprising a signature of up to 54 genes, and including also sub-sets of genes within the signature, which can identify members by requiring higher correlation values for a signature gene. The present mitotic network provides for methods for prognosis and diagnosis of various cancers. The mitotic network is conserved across cancers exhibiting aberrant mitotic activity and several genes in the network act as therapeutic targets. Development of other inhibitors of mitosis can apply expression values of the genes in the mitotic network from patient tissue to select patients during clinical validation of the new drugs.

Abstract: The present application provides compositions and methods useful for treating and diagnosing diseases and disorders associated with moesin activation.

Abstract: The present invention provides compositions and methods useful for detecting and monitoring autoimmune diseases.

Abstract: The present application provides compositions and methods useful for detecting and monitoring acquired aplastic anemia.

Abstract: This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.

Abstract: A halogenated dideoxy sugar derivative, having the following general structure I wherein X is halogen, R1 and R2 are H or Br; R3 and R4 are OH or OAc. The compounds 1-14 of the current invention has strong inhibition effect on human nasopharyngeal cancer CNE-2Z cells, human lung cancer A549 cells. human colon cancer HT-29 cells, human liver cancer Bel-7402 cells, human rectum cancer cells HCE 8693, human stomach cancer BGC-803 cells, human esophagus cancer CaEs-17 cells, human breast cancer cells MCF-7, human ovarian cancer cells A2780, pancreatic cancer cells PC-3, human bladder cells EJ, human brain glia cells TG-905, human leukemia cells K562, human melanoma M 14 cells and human anaplastic thyroid carcinoma TA-K cells. They can be used to prepare anti-tumor medicament and have significant clinic value.

Abstract: Developed here is a mitotic network comprising a signature of up to 54 genes, and including also sub-sets of genes within the signature, which can identify members by requiring higher correlation values for a signature gene. The present mitotic network provides for methods for prognosis and diagnosis of various cancers. The mitotic network is conserved across cancers exhibiting aberrant mitotic activity and several genes in the network act as therapeutic targets. Development of other inhibitors of mitosis can apply expression values of the genes in the mitotic network from patient tissue to select patients during clinical validation of the new drugs.

Abstract: Provided is an electrical connector including an insulative housing having a main body and a pair of tongue plates perpendicular extending from said main body along a mating direction. Said tongue plates are parallel to each other and each defines a plurality of terminal grooves thereon. A plurality of terminals are received in the terminal grooves. A metallic shell is retained on the main body of the insulative housing and encloses said pair of tongue plates thereby defining a mating opening therein. The mating opening defines a first and a second different interfaces in communication with each other. At least a partition portion protrudes toward the mating opening from said main body and defines a bottom surface to act as a top wall of the second interface.

Abstract: A receptacle connector comprises an insulative housing having a base portion; a plurality of terminals retained in the insulative housing; a shielding shell assembled on the base portion of the insulative housing and defined a mating cavity. A reinforced bracket includes a main portion attached to a bottom of the shielding shell and a pair of mounting portions extending from two ends of the main portion. Therefore, overall rigidity of the receptacle connector may be increased.

Abstract: A low profile connector for mounting on a PCB comprising: an insulative housing, a plurality of terminals, a shielding shell and an auxiliary member. Each terminal is provided with a contacting section and a solder portion extending beyond insulative housing for connecting with the PCB. The shielding shell defines a mating opening surrounding the contact portion, and the auxiliary member defines a main portion attached to a bottom surface of the shielding shell and at least one horizontal portion located at one end thereof for mounting on an upper surface of the PCB. The shielding shell further includes a vertical portion perpendicular to the horizontal portion for inserting a hole of the PCB, and the horizontal portion of the auxiliary member has a concavity for receiving the vertical portion which decreasing space that the connector located on the PCB.

Abstract: An electrical connector includes an insulative housing (1) with a rear portion (11) and a front portion (12) along a first direction (A), a spacer (4) assembled on the rear portion (11) which has a plurality of first wedged positioning sections (42, 43) in an inner side thereof and arranged along a second direction (B) and a plurality of contacts (2) received in the insulative housing and comprising a soldering portion (203) extending out of the insulative housing. The spacer (4) includes a plurality of positioning grooves (45) in an external side thereof for receiving and positioning the soldering portions (203c) of one part contacts (23) located at an upper side of the front portion (12). The soldering portions (203a, 203b) of the other contacts (21a, 21b) are sandwiched between the spacer (4) and the rear portion (11) thereby forms a waved configuration.